Operating
Income Loss From Equity Method Investments Net Of Dividends Or Distributions
West Pharmaceutical Services Income Loss From Equity Method Investments Net Of Dividends Or Distributions remained flat by 0.0% to $2.63M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 21.6%, from $3.35M to $2.63M. Over 4 years (FY 2021 to FY 2025), Income Loss From Equity Method Investments Net Of Dividends Or Distributions shows a downward trend with a -11.9% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2013
Last reportedQ4 2025Feb 17, 2026
Metric ID:
operating_income_loss_from_equity_method_investments_net_3458a6Historical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $17.4M | $18.1M | $14.3M | $13.4M | $10.5M |
| YoY Change | — | +4.0% | -21.0% | -6.3% | -21.6% |
Range$10.5M – $18.1M
CAGR-11.9%
Avg YoY Growth-11.2%
Median YoY Growth-13.6%
Current Streak3 years decline
Income Loss From Equity Method Investments Net Of Dividends Or Distributions at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's income loss from equity method investments net of dividends or distributions?
- West Pharmaceutical Services (WST) reported income loss from equity method investments net of dividends or distributions of $2.63M in Q4 2025.
- How has West Pharmaceutical Services's income loss from equity method investments net of dividends or distributions changed year-over-year?
- West Pharmaceutical Services's income loss from equity method investments net of dividends or distributions decreased by 21.6% year-over-year, from $3.35M to $2.63M.
- What is the long-term trend for West Pharmaceutical Services's income loss from equity method investments net of dividends or distributions?
- Over 4 years (2021 to 2025), West Pharmaceutical Services's income loss from equity method investments net of dividends or distributions has grown at a -11.9% compound annual growth rate (CAGR), from $17.4M to $10.5M.